After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

A century ago, the strange behavior of atoms and elementary particles led physicists to formulate a new theory of nature. That theory, quantum mechanics, found immediate success, proving its worth ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

A global team led by Michal Holčapek, professor of analytical chemistry at the Faculty of Chemical Technology, UPCE, Pardubice (Czech Republic), and Jakub Idkowiak, a research associate from KU Leuven ...

These are direct-prediction models trained from scratch on small, heavily augmented datasets—not few-shot prompting. ARC remains the canonical target; broader leaderboard context and rules (e.g., ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

If you’d like an LLM to act more like a partner than a tool, Databot is an experimental alternative to querychat that also works in both R and Python. Databot is designed to analyze data you’ve ...

Why write SQL queries when you can get an LLM to write the code for you? Query NFL data using querychat, a new chatbot component that works with the Shiny web framework and is compatible with R and ...

Palantir's stock is up nearly 10 % month-to-date and has gone even higher year-to-date, as bullish sentiment surges ahead of its second quarter earnings. Tempus AI shares, currently at about $64, have ...